ATE465164T1 - Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten - Google Patents

Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten

Info

Publication number
ATE465164T1
ATE465164T1 AT07729660T AT07729660T ATE465164T1 AT E465164 T1 ATE465164 T1 AT E465164T1 AT 07729660 T AT07729660 T AT 07729660T AT 07729660 T AT07729660 T AT 07729660T AT E465164 T1 ATE465164 T1 AT E465164T1
Authority
AT
Austria
Prior art keywords
treatment
degenerational
inflammatory diseases
compounds
triazolopyrazine
Prior art date
Application number
AT07729660T
Other languages
English (en)
Inventor
Martin James Inglis Andrews
Paul Edwards
Mark Stuart Chambers
Wolfgang Schmidt
Juha Andrew Clase
Gregory Bar
Kim Louise Hirst
Angus Macleod
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Application granted granted Critical
Publication of ATE465164T1 publication Critical patent/ATE465164T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT07729660T 2006-05-31 2007-05-30 Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten ATE465164T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80355206P 2006-05-31 2006-05-31
US93176307P 2007-05-25 2007-05-25
US93176407P 2007-05-25 2007-05-25
US93184407P 2007-05-25 2007-05-25
US93210007P 2007-05-29 2007-05-29
PCT/EP2007/055246 WO2007138072A2 (en) 2006-05-31 2007-05-30 Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE465164T1 true ATE465164T1 (de) 2010-05-15

Family

ID=38618932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07729660T ATE465164T1 (de) 2006-05-31 2007-05-30 Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten

Country Status (20)

Country Link
US (3) US7501411B2 (de)
JP (1) JP2009538877A (de)
KR (1) KR20090026288A (de)
AT (1) ATE465164T1 (de)
AU (1) AU2007267121A1 (de)
BR (1) BRPI0712531A2 (de)
CA (1) CA2653506A1 (de)
CR (1) CR10458A (de)
DE (1) DE602007006010D1 (de)
DK (1) DK2029602T3 (de)
EA (1) EA200870592A1 (de)
EC (1) ECSP088923A (de)
HR (1) HRP20100378T1 (de)
IL (1) IL195033A0 (de)
MX (1) MX2008015057A (de)
NI (1) NI200800299A (de)
NO (1) NO20084703L (de)
NZ (1) NZ573015A (de)
PT (1) PT2029602E (de)
WO (1) WO2007138072A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097800A1 (en) 2004-04-02 2005-10-20 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
DE602007006010D1 (de) * 2006-05-31 2010-06-02 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
ATE495743T1 (de) 2006-12-01 2011-02-15 Galapagos Nv Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2008138843A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases
WO2008138842A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
DE102008035209A1 (de) 2008-07-29 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102007060172A1 (de) 2007-12-13 2009-06-25 Bayer Healthcare Ag Triazolotriazine und Triazolopyrazine und ihre Verwendung
CL2009001064A1 (es) * 2008-05-07 2009-10-09 Galapagos Nv Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide.
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基***并吡啶，其組合物及使用其之治療方法
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
EP2427192A1 (de) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Verwendung von osi-906 zur behandlung von adrenokortikalem karzinom
TW201120043A (en) * 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
EP2343297A1 (de) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
PT3008062T (pt) 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
CN105339370B (zh) * 2013-06-19 2017-09-15 加拉帕戈斯股份有限公司 用于治疗炎症性疾病的化合物和及其药物组合物
MX2016008653A (es) 2014-01-03 2016-09-26 Bayer Animal Health Gmbh Nuevas pirazolil-heteroarilamidas como agentes plaguicidas.
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
KR20180030545A (ko) 2015-06-22 2018-03-23 다이닛본 스미토모 세이야꾸 가부시끼가이샤 바이사이클릭 헤테로사이클릭 아미드 유도체
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017146128A1 (ja) * 2016-02-26 2017-08-31 大日本住友製薬株式会社 イミダゾリルアミド誘導体
KR20230156174A (ko) 2016-07-12 2023-11-13 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
SG11201906164RA (en) 2017-01-11 2019-08-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
AU2018210196B2 (en) 2017-01-23 2022-06-02 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
CN109206357A (zh) * 2017-07-04 2019-01-15 浙江九洲药业股份有限公司 一种格列齐特中间体的通式化合物及其制备方法和应用
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
RU2020123241A (ru) 2017-12-15 2022-01-17 Революшн Медсинз, Инк. Полициклические соединения в качестве аллостерических ингибиторов shp2
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CN108379583B (zh) * 2018-03-27 2021-08-17 北京大学 一种肿瘤转移药物治疗的靶标及其应用
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
CA2386813C (en) 1999-10-08 2008-09-02 Grunenthal Gmbh Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring
SK286788B6 (sk) 1999-10-08 2009-05-07 Grnenthal Gmbh Bicyklické deriváty imidazo-3-yl-amínu, spôsob ich výroby, ich použitie a liečivá obsahujúce tieto látky
CA2388476C (en) 1999-10-08 2008-08-05 Gruenenthal Gmbh Bicyclic imidazo-5-yl-amine derivatives
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
NO311460B1 (no) 2000-07-14 2001-11-26 Zopa As Fremgangsmåte og anordning for kjöling av produkter i et transportsystem
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
EP1363702A4 (de) * 2001-01-30 2007-08-22 Cytopia Pty Ltd Verfahren zur hemmung von kinasen
BR0309398A (pt) * 2002-04-19 2005-02-01 Cellular Genomics Inc Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase
EP1543008B1 (de) * 2002-09-23 2007-11-07 Schering Corporation Imidazopyrazine als cdk-inhibitoren
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
JP4916883B2 (ja) * 2003-10-15 2012-04-18 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤
WO2005085252A1 (en) 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
CA2570073A1 (en) 2004-06-09 2005-12-22 Oncalis Ag Protein kinase inhibitors
JP4935357B2 (ja) 2004-11-08 2012-05-23 Ｍｓｄ株式会社 新規縮環イミダゾール誘導体
EP1812442A2 (de) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamin-derivate verwendbar als kinase modulatoren
US20060149535A1 (en) * 2004-12-30 2006-07-06 Lg Electronics Inc. Method for controlling speed of audio signals
WO2006086545A2 (en) 2005-02-08 2006-08-17 Robert W Desimone Method to identify novel therapeutics
BRPI0608252A2 (pt) 2005-03-10 2010-04-06 Cgi Pharmaceuticals Inc entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
EP1928237A4 (de) 2005-09-02 2011-03-09 Abbott Lab Neue heterocyclen auf imidazo-basis
RU2008122967A (ru) * 2005-11-10 2009-12-20 Шеринг Корпорейшн (US) Имидазопиразины в качестве ингибиторов протеинкиназ
EP1945216A1 (de) 2005-11-10 2008-07-23 Schering Corporation Verfahren zur hemmung von proteinkinasen
EP1957458A2 (de) 2005-12-01 2008-08-20 Elan Pharmaceuticals Inc. 5-(arylsulfonyl)pyrazolopiperidine
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
DE602007006010D1 (de) * 2006-05-31 2010-06-02 Galapagos Nv Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors

Also Published As

Publication number Publication date
US7915256B2 (en) 2011-03-29
US7501411B2 (en) 2009-03-10
KR20090026288A (ko) 2009-03-12
PT2029602E (pt) 2010-07-08
JP2009538877A (ja) 2009-11-12
WO2007138072A3 (en) 2008-02-14
US20110178067A1 (en) 2011-07-21
US20080090818A1 (en) 2008-04-17
AU2007267121A1 (en) 2007-12-06
NI200800299A (es) 2010-05-25
NZ573015A (en) 2010-11-26
WO2007138072A2 (en) 2007-12-06
DK2029602T3 (da) 2010-08-09
IL195033A0 (en) 2009-08-03
DE602007006010D1 (de) 2010-06-02
ECSP088923A (es) 2009-01-30
CR10458A (es) 2009-02-26
MX2008015057A (es) 2008-12-10
HRP20100378T1 (hr) 2010-08-31
US20100298300A1 (en) 2010-11-25
BRPI0712531A2 (pt) 2012-12-25
EA200870592A1 (ru) 2009-08-28
NO20084703L (no) 2009-02-19
CA2653506A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
ATE465164T1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
UA100007C2 (ru) Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
DK1869049T3 (da) Imidazopyridazinforbindelser
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
GEP20125565B (en) Lactam compounds and their pharmaceutical use
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
EP2215054B8 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
WO2005105770A3 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
EA201071275A1 (ru) Конденсированные соединения пиразина, которые можно использовать для лечения дегенеративных и воспалительных заболеваний
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
WO2006099410A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
TW200503703A (en) Pharmaceutical compositions
WO2005105766A3 (en) Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them
WO2005016272A3 (en) Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
DE602004006024D1 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
EA200701835A1 (ru) Амидные производные в качестве лигандов ионных каналов, их фармацевтические композиции и способы их применения
GB2452142A (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EA200702274A1 (ru) Твёрдые кристаллические и аморфные формы (-)-галофената и способ их получения, фармацевтическая композиция на их основе и способ лечения
WO2005037208A3 (en) Nitrone compounds prodrugs and pharmaceutical compositions of the same to treat human disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2029602

Country of ref document: EP